Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 16.02 as of 2026-10-02T20:35:54.232Z.
Consensus retrieved: 2026-10-02T16:44:24.605Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-02T20:35:54.232Z.
Quote observation: 2026-10-02T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0be53b889a34275f00216ff99dc3094d43fc397a65c15d72f0e0b892efd9cb96
Forward PE Ratio (16.02) = Dated Quote Price ($141.00) / Consensus Forward EPS ($8.80)
FORWARD PE RATIO
16.02
SECTOR MEDIAN · HEALTHCARE
18.80
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-14.79%
vs the sector median at left
Novartis AG
Market Cap
$268.00B
Forward PE Ratio
16.02
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Novartis AG (NVS) | $268.00B | 16.02 |
| AstraZeneca PLC (AZN)vs › | $243.33B | 15.28 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $242.11B | 26.08 |
| Amgen Inc. (AMGN)vs › | $217.52B | 17.47 |
| Roche Holding AG (RHHBY)vs › | $332.94B | N/A |
| UnitedHealth Group Incorporated (UNH)vs › | $337.74B | 18.64 |
| Merck & Co., Inc. (MRK)vs › | $356.40B | 52.76 |
| Gilead Sciences, Inc. (GILD)vs › | $179.47B | N/A |
| Abbott Laboratories (ABT)vs › | $168.71B | 17.67 |
| Novo Nordisk A/S (NVO)vs › | $165.72B | N/A |
Trailing P/E
21.3
reported TTM EPS
Forward P/E
16.0
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $8.80 implies +32.7% EPS growth vs the reported trailing $6.63.
At the dated quote price of $141.00, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $8.80 | $8.55 – $9.07 | 8 | 16.0x |
| 2027-12-31 | $9.80 | $9.68 – $9.98 | 9 | 14.4x |
| 2028-12-31 | $10.79 | $10.45 – $11.33 | 4 | 13.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
